Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 1
1992 2
1993 1
1995 5
1996 2
1997 5
1998 3
1999 3
2000 11
2002 1
2003 1
2004 4
2005 2
2006 5
2007 2
2008 1
2011 1
2012 2
2013 1
2014 1
2015 1
2016 2
2017 1
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Trial to Reconfirm the Efficacy and Safety of Cefetamet Pivoxil Treatment in Sinusitis Patients: A Double-Blind, Randomized, Parallel Designed, Multicenter, Active Comparator Study (CASIS Study).
Park CS, Cho JH, Lee HM, Kim KS, Kim JK, Kim DY, Baek BJ, Kim HJ, Kim YD, Hwang CS, Kim ST, Cho SH, Kim YM, Lee SH, Jeong JH, In SM, Kim BG. Park CS, et al. Ear Nose Throat J. 2023 Feb;102(2):101-109. doi: 10.1177/01455613211036236. Epub 2021 Aug 24. Ear Nose Throat J. 2023. PMID: 34427151 Free article. Clinical Trial.
RESULTS: Treatment with cefetamet pivoxil for 2 weeks showed 82.4% clinical cure and improvement rates in patients with acute bacterial rhinosinusitis compared to 84.68% in those taking cefdinir for 2 weeks, showing that cefetamet pivoxil administered twice a day for 2 wee …
RESULTS: Treatment with cefetamet pivoxil for 2 weeks showed 82.4% clinical cure and improvement rates in patients with acute bacterial rhin …
[Pharmacokinetic and clinical studies of cefdinir in the pediatric field. Pediatric Study Group of Cefdinir].
Fujii R, Yoshioka H, Fujita K, Sakata H, Nire H, Iseki K, Murono K, Takahashi Y, Wagatsuma Y, Fukushima N, et al. Fujii R, et al. Jpn J Antibiot. 1991 Oct;44(10):1168-91. Jpn J Antibiot. 1991. PMID: 1762172 Clinical Trial. Japanese.
We studied pharmacokinetics and clinical effects of 5% and 10% fine granules of cefdinir (FK 482, CFDN), a new oral cephalosporin, in the pediatric field and the following results were obtained. 1. ...
We studied pharmacokinetics and clinical effects of 5% and 10% fine granules of cefdinir (FK 482, CFDN), a new oral cephalosporin, in …
Comparison of cefdinir and penicillin for the treatment of streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.
Nemeth MA, McCarty J, Gooch WM 3rd, Henry D, Keyserling CH, Tack KJ. Nemeth MA, et al. Clin Ther. 1999 Nov;21(11):1873-81. doi: 10.1016/s0149-2918(00)86735-1. Clin Ther. 1999. PMID: 10890259 Clinical Trial.
The eradication rates 4 to 9 days after completion of therapy were 91.4% in the cefdinir QD group, 91.7% in the cefdinir BID group, and 83.4% in the penicillin group (P = 0.02 for cefdinir QD vs penicillin, P = 0.01 for cefdinir BID vs penicillin, P = …
The eradication rates 4 to 9 days after completion of therapy were 91.4% in the cefdinir QD group, 91.7% in the cefdinir BID g …
Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.
Tack KJ, Littlejohn TW, Mailloux G, Wolf MM, Keyserling CH. Tack KJ, et al. Clin Ther. 1998 Mar-Apr;20(2):244-56. doi: 10.1016/s0149-2918(98)80088-x. Clin Ther. 1998. PMID: 9589816 Clinical Trial.
Cefdinir taken BID was as effective as cephalexin taken QID in the treatment of mild-to-moderate SSSIs and was well tolerated by most patients. The increased antibacterial activity of cefdinir must be balanced against the higher rate of diarrhea seen in patients tre
Cefdinir taken BID was as effective as cephalexin taken QID in the treatment of mild-to-moderate SSSIs and was well tolerated by most
Clinical and economic considerations in the use of third-generation oral cephalosporins.
Chambers ST, Murdoch DR, Pearce MJ. Chambers ST, et al. Pharmacoeconomics. 1995 May;7(5):416-27. doi: 10.2165/00019053-199507050-00006. Pharmacoeconomics. 1995. PMID: 10155329 Review.
A number of oral third-generation cephalosporins (cefixime, cefetamet pivoxil, ceftibuten and cefpodoxime proxetil) have been widely trialled and are becoming available. In addition, cefdinir may also be marketed. Compared with first- and second-generation agents, the oral …
A number of oral third-generation cephalosporins (cefixime, cefetamet pivoxil, ceftibuten and cefpodoxime proxetil) have been widely trialle …
Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.
Gwaltney JM Jr, Savolainen S, Rivas P, Schenk P, Scheld WM, Sydnor A, Keyserling C, Leigh A, Tack KJ. Gwaltney JM Jr, et al. Antimicrob Agents Chemother. 1997 Jul;41(7):1517-20. doi: 10.1128/AAC.41.7.1517. Antimicrob Agents Chemother. 1997. PMID: 9210677 Free PMC article. Clinical Trial.
Cefdinir is an extended-spectrum oral cephalosporin that is active against pathogens commonly seen in acute community-acquired bacterial sinusitis (ACABS), including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. ...The major side effect was m
Cefdinir is an extended-spectrum oral cephalosporin that is active against pathogens commonly seen in acute community-acquired bacter
Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group.
Tack KJ, Henry DC, Gooch WM, Brink DN, Keyserling CH. Tack KJ, et al. Antimicrob Agents Chemother. 1998 May;42(5):1073-5. doi: 10.1128/AAC.42.5.1073. Antimicrob Agents Chemother. 1998. PMID: 9593129 Free PMC article. Clinical Trial.
Both treatments were well tolerated, with adverse reaction rates of 18.3% in the cefdinir study arm and 15.0% in the penicillin study arm (P = 0.278). Five-day treatment with cefdinir is safe and effective therapy for GABHS pharyngitis. Based on its twice-a-day dosa …
Both treatments were well tolerated, with adverse reaction rates of 18.3% in the cefdinir study arm and 15.0% in the penicillin study …
Lack of interaction between cefdinir and calcium polycarbophil: in vitro and in vivo studies.
Kato R, Ooi K, Takeda K, Mashimo K, Fujimura Y, Kusumoto M, Ueno K. Kato R, et al. Drug Metab Pharmacokinet. 2002;17(4):363-6. doi: 10.2133/dmpk.17.363. Drug Metab Pharmacokinet. 2002. PMID: 15618687 Free article. Clinical Trial.
The effect of calcium polycarbophil on the absorption of cefdinir, cephalosporin derivative, was evaluated in both in vitro and in vivo studies. ...In the in vivo study, volunteers and a randomized crossover design with two phases were used. In the first phase, the volunte …
The effect of calcium polycarbophil on the absorption of cefdinir, cephalosporin derivative, was evaluated in both in vitro and in vi …
Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy.
Block SL, Hedrick JA, Kratzer J, Nemeth MA, Tack KJ. Block SL, et al. Pediatr Infect Dis J. 2000 Dec;19(12 Suppl):S153-8. doi: 10.1097/00006454-200012001-00004. Pediatr Infect Dis J. 2000. PMID: 11144397 Clinical Trial.
OBJECTIVE: To examine the microbiologic and clinical efficacy of a 5-day course of cefdinir in the treatment of tympanocentesis-documented acute otitis media (AOM). ...Cefdinir should be considered a suitable second line antibiotic for AOM....
OBJECTIVE: To examine the microbiologic and clinical efficacy of a 5-day course of cefdinir in the treatment of tympanocentesis-docum …
Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis.
Nemeth MA, Gooch WM 3rd, Hedrick J, Slosberg E, Keyserling CH, Tack KJ. Nemeth MA, et al. Clin Ther. 1999 Sep;21(9):1525-32. doi: 10.1016/s0149-2918(00)80007-7. Clin Ther. 1999. PMID: 10509847 Clinical Trial.
Clinical cure rates were 97.4%, 96.0%, and 86.3% for the cefdinir QD, cefdinir BID, and penicillin groups, respectively (CI 6.1%-15.9%, P = 0.001 for cefdinir QD vs penicillin; CI 4.6%-14.8%, P = 0.001 for cefdinir BID vs penicillin). Adverse reactions …
Clinical cure rates were 97.4%, 96.0%, and 86.3% for the cefdinir QD, cefdinir BID, and penicillin groups, respectively (CI 6. …
60 results